1. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety;Auclair;Neuropharmacology,2013
2. Forest Laboratories, Inc. Forest Laboratories and Pierre Fabre Laboratories announce FDA approval of FETZIMA for the treatment of major depressive disorder in adults. Press Release 2013 http://frx.investorhq.businesswire.com/press-release/corporate-news/forest-laboratories-and-pierre-fabre-laboratories-announce-fda-approval
3. Forest Pharmaceuticals, Inc FETZIMA (levomilnacipran). Prescribing information 2013 http://www.frx.com/pi/Fetzima_pi.pdf
4. Which bioequivalence study for a racemic drug? Application to milnacipran;Deprez;Eur J Drug Metab Pharmacokinet,1998
5. Enantioselective synthesis of levomilnacipran;Alliot;Chem Commun (Camb),2012